Why Bausch + Lomb’s ASCRS 2026 data slate matters for premium IOL competition and dry eye care
Find out why Bausch + Lomb’s ASCRS 2026 data package could reshape competition in cataract surgery, dry eye care, and ophthalmology platforms.
What Affinia Therapeutics’ UPBEAT trial reveals about the next phase of inherited heart failure gene therapy
Affinia Therapeutics has cleared AFTX-201 for a Canadian BAG3 DCM trial. Read why the gene therapy’s design and risks matter now.
How Florida Cancer Specialists contributed to a study that may change KRAS G12D cancer treatment
Setidegrasib showed early activity in KRAS G12D lung and pancreatic cancers. Read why the Phase 1 signal could matter for oncology’s next target.
Why Vyome’s VT-1953 data could reshape supportive oncology care in advanced cancer wounds
Vyome’s VT-1953 heads to AACR 2026 with Phase 2 data in malignant fungating wounds. Read what this could change for supportive oncology.
Can ZIVO Bioscience finally scale Zivolife after securing Cyanotech as its manufacturing partner?
ZIVO Bioscience’s Cyanotech deal could reshape the Zivolife commercialization story. Read why manufacturing may now matter more than hype.
Is Alcon redefining the enhanced monofocal category with Clareon TruPlus at ASCRS 2026?
Alcon launched Clareon TruPlus at ASCRS 2026. Read why the new enhanced monofocal IOL could reshape cataract lens choice.
Why ABION’s ABN202 may be aiming beyond TROP2 antibody-drug conjugate resistance
ABION’s ABN202 showed preclinical promise against TROP2 ADC resistance at AACR 2026. Read what this could mean for solid tumor oncology.
What the Nexus Pharmaceuticals cyclophosphamide launch reveals about competition in sterile generic oncology drugs
Nexus Pharmaceuticals has launched cyclophosphamide injection in ready-to-dilute vials. Read what this means for oncology workflows and generic drug access.
Can Evommune turn EVO756 into a cross-indication inflammatory franchise with migraine next?
Evommune is taking EVO756 into migraine prophylaxis. Read why MRGPRX2 inhibition could matter, and what risks still cloud the story.
ESMO-EURACAN adds CHEMOSAT to uveal melanoma guidance as Delcath Systems strengthens clinical position
Delcath Systems won ESMO-EURACAN guideline recognition for CHEMOSAT in uveal melanoma. Read what this could change for liver-directed cancer care.